Product Code: ETC13278730 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Intravenous Immunoglobulin Market was valued at USD 20.5 Billion in 2024 and is expected to reach USD 29.9 Billion by 2031, growing at a compound annual growth rate of 4.30% during the forecast period (2025-2031).
The Global Intravenous Immunoglobulin Market is experiencing significant growth driven by increasing prevalence of immunodeficiency disorders, autoimmune diseases, and neurological disorders. The market is characterized by the presence of key players such as Grifols, CSL Behring, Takeda Pharmaceutical, and Octapharma AG who are investing in research and development activities to introduce innovative products. Rising awareness among healthcare professionals and patients regarding the benefits of intravenous immunoglobulin therapy is also fueling market growth. Additionally, the expanding geriatric population and the growing demand for immunoglobulin products in emerging economies are contributing to the market expansion. However, stringent regulatory policies and the high cost associated with intravenous immunoglobulin therapy may hinder market growth to some extent. Overall, the Global Intravenous Immunoglobulin Market is poised for continued growth in the coming years.
The Global Intravenous Immunoglobulin (IVIG) Market is experiencing growth driven by the increasing prevalence of autoimmune and immunodeficiency disorders, as well as rising awareness about IVIG therapy. The market is witnessing a shift towards the development of advanced formulations and targeted therapies to enhance efficacy and reduce side effects. Additionally, the expanding applications of IVIG in neurology, hematology, and immunology are creating new opportunities for market players. Technological advancements such as the use of recombinant IVIG and the development of subcutaneous formulations are also contributing to market growth. With the increasing adoption of IVIG in emerging markets and the rising investment in research and development activities, the Global IVIG Market is poised for continued expansion in the coming years.
One of the key challenges faced in the Global Intravenous Immunoglobulin Market is the limited availability of plasma donors, which is the primary raw material for manufacturing IV immunoglobulin products. This constraint can lead to supply shortages and price fluctuations in the market. Additionally, stringent regulatory requirements for the production and distribution of IV immunoglobulin products pose challenges for manufacturers in terms of compliance and market entry. Furthermore, the high cost of IV immunoglobulin therapy can be a barrier for patients, particularly in emerging markets with limited healthcare infrastructure and financial resources. Overall, the Global IV Immunoglobulin Market is characterized by complex supply chain dynamics, regulatory hurdles, and pricing pressures, which present challenges for market players across the value chain.
The Global Intravenous Immunoglobulin Market is primarily driven by increasing incidences of immune deficiency disorders, autoimmune diseases, and neurological disorders such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The rising geriatric population, who are more susceptible to these conditions, is also contributing to the market growth. Additionally, advancements in healthcare infrastructure and increasing awareness about the benefits of intravenous immunoglobulin therapy are further propelling market expansion. The ongoing research and development activities to enhance the efficacy and safety profile of intravenous immunoglobulin products are expected to drive market growth in the forecast period. Furthermore, the expanding applications of intravenous immunoglobulin in various therapeutic areas are creating new opportunities for market players to innovate and expand their product portfolio.
Government policies related to the Global Intravenous Immunoglobulin Market typically focus on ensuring the safety, efficacy, and availability of these products. Regulatory agencies such as the FDA in the United States and the EMA in Europe oversee the approval, manufacturing, and distribution of intravenous immunoglobulin products. These agencies set strict guidelines for quality control, labeling, and post-market surveillance to safeguard patient health. Additionally, governments may implement policies to promote access to intravenous immunoglobulin for patients with specific medical conditions or rare diseases through reimbursement schemes or subsidies. Overall, government policies aim to maintain a competitive market while prioritizing patient safety and ensuring equitable access to these essential therapies.
The Global Intravenous Immunoglobulin Market is expected to witness steady growth in the coming years due to increasing prevalence of autoimmune diseases, infectious diseases, and neurological disorders. Rising geriatric population, advancements in healthcare infrastructure, and growing awareness about the benefits of intravenous immunoglobulin therapy are also driving market growth. Additionally, the expanding applications of IVIG in various therapeutic areas such as immunodeficiency disorders, inflammatory diseases, and hematological conditions are expected to further boost market expansion. However, challenges such as high costs associated with IVIG therapy, stringent regulatory requirements, and limited availability of plasma donors may hinder market growth to some extent. Overall, the market is poised for growth with opportunities for market players to innovate and expand their product offerings to meet the increasing demand for intravenous immunoglobulin therapy globally.
In the Global Intravenous Immunoglobulin Market, Asia is expected to witness significant growth due to increasing healthcare expenditure and rising prevalence of immunodeficiency disorders in countries like China and India. North America is likely to dominate the market owing to advanced healthcare infrastructure and high adoption of IV immunoglobulin therapy. Europe is anticipated to hold a substantial market share due to the presence of key players and growing awareness about immunodeficiency disorders. The Middle East and Africa region is expected to show moderate growth due to improving healthcare facilities and rising investments in healthcare. Latin America is poised for steady growth driven by increasing government initiatives to improve healthcare access and rising prevalence of autoimmune diseases in countries like Brazil and Mexico.
Global Intravenous Immunoglobulin Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Intravenous Immunoglobulin Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Intravenous Immunoglobulin Market Revenues & Volume, 2021 & 2031F |
3.3 Global Intravenous Immunoglobulin Market - Industry Life Cycle |
3.4 Global Intravenous Immunoglobulin Market - Porter's Five Forces |
3.5 Global Intravenous Immunoglobulin Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Intravenous Immunoglobulin Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Global Intravenous Immunoglobulin Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Global Intravenous Immunoglobulin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Intravenous Immunoglobulin Market Trends |
6 Global Intravenous Immunoglobulin Market, 2021 - 2031 |
6.1 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2021 - 2031 |
6.1.3 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Primary Humoral Immunodeficiency, 2021 - 2031 |
6.1.4 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Idiopathic Thrombocytopenic Purpura (ITP), 2021 - 2031 |
6.1.5 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Guillain-Barre Syndrome, 2021 - 2031 |
6.1.6 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Myasthenia Gravis, 2021 - 2031 |
6.1.7 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Multifocal Motor Neuropathy (MMN), 2021 - 2031 |
6.1.8 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Kawasaki Disease, 2021 - 2031 |
6.1.9 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Others, 2021 - 2031 |
6.2 Global Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Hospitals, 2021 - 2031 |
6.2.3 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Clinics, 2021 - 2031 |
6.2.4 Global Intravenous Immunoglobulin Market, Revenues & Volume, By Home Care, 2021 - 2031 |
6.3.1 Overview & Analysis |
7 North America Intravenous Immunoglobulin Market, Overview & Analysis |
7.1 North America Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
7.2 North America Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.4 North America Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
8 Latin America (LATAM) Intravenous Immunoglobulin Market, Overview & Analysis |
8.1 Latin America (LATAM) Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
8.4 Latin America (LATAM) Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
9 Asia Intravenous Immunoglobulin Market, Overview & Analysis |
9.1 Asia Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
9.4 Asia Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
10 Africa Intravenous Immunoglobulin Market, Overview & Analysis |
10.1 Africa Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
10.4 Africa Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
11 Europe Intravenous Immunoglobulin Market, Overview & Analysis |
11.1 Europe Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
11.4 Europe Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
12 Middle East Intravenous Immunoglobulin Market, Overview & Analysis |
12.1 Middle East Intravenous Immunoglobulin Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Intravenous Immunoglobulin Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Intravenous Immunoglobulin Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Intravenous Immunoglobulin Market, Revenues & Volume, By Indication, 2021 - 2031 |
12.4 Middle East Intravenous Immunoglobulin Market, Revenues & Volume, By End-user, 2021 - 2031 |
13 Global Intravenous Immunoglobulin Market Key Performance Indicators |
14 Global Intravenous Immunoglobulin Market - Export/Import By Countries Assessment |
15 Global Intravenous Immunoglobulin Market - Opportunity Assessment |
15.1 Global Intravenous Immunoglobulin Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Intravenous Immunoglobulin Market Opportunity Assessment, By Indication, 2021 & 2031F |
15.3 Global Intravenous Immunoglobulin Market Opportunity Assessment, By End-user, 2021 & 2031F |
16 Global Intravenous Immunoglobulin Market - Competitive Landscape |
16.1 Global Intravenous Immunoglobulin Market Revenue Share, By Companies, 2024 |
16.2 Global Intravenous Immunoglobulin Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |